SCHEMBL8284306

SCHEMBL8284306

CC[C@@H](N)c1cc(C)ccc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
TAAR1 Q96RJ0 1/20 0.39
KDM4E B2RXH2 2/20 0.34
LMNA P02545 2/20 0.34
SLC6A4 P31645 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
THRB P10828 1/20 0.33
ALOX15 P16050 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
TACR1 P25103 1/20 0.33
DPP8 Q6V1X1 2/20 0.33
DPP9 Q86TI2 2/20 0.33
NR3C1 P04150 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19231144 1.00 ALDH1A1 (0.41) ALDH1A1TDP1TAAR1KDM4ELMNA
Hydrochloric Acid SCHEMBL4927027 0.98 ALDH1A1 (0.40) ALDH1A1TDP1TAAR1KDM4ELMNA
Hydrochloric Acid SCHEMBL23527453 0.98 ALDH1A1 (0.40) ALDH1A1TDP1TAAR1KDM4ELMNA
SCHEMBL8286737 0.83 TDP1 (0.37) ALDH1A1TDP1TAAR1LMNASLC6A4
SCHEMBL14168940 0.83 TDP1 (0.37) ALDH1A1TDP1TAAR1LMNASLC6A4
SCHEMBL11659436 0.83 TAAR1 (0.44) ALDH1A1TDP1TAAR1KDM4ELMNA
SCHEMBL8284228 0.83 TDP1 (0.37) ALDH1A1TDP1TAAR1LMNASLC6A4
Hydrochloric Acid SCHEMBL4934492 0.82 TAS1R3 (0.36) ALDH1A1TDP1TAAR1LMNASLC6A4
SCHEMBL18515356 0.82 ALDH1A1 (0.40) ALDH1A1TDP1TAAR1KDM4ELMNA
SCHEMBL29346005 0.80 HTR2A (0.36) SLC6A4DPP8DPP9DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691962-B2 Therapeutic compounds and compositions EXITHERA PHARMACEUTICALS, INC. (US) 2023-07-04 US disclosed
US-11691962-B2 Therapeutic compounds and compositions EXITHERA PHARMACEUTICALS, INC. (US) 2023-07-04 US disclosed
US-20210188812-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS Cadrenal Therapeutics, Inc. 2021-06-24 US disclosed
WO-2019156929-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS eXIthera Pharmaceuticals Inc. (US) 2019-08-15 WO disclosed
US-20080132536-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED 2008-06-05 US disclosed
US-20080132536-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED 2008-06-05 US disclosed
US-20070111995-A1 Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors GLAXO GROUP LIMITED (GB) 2007-05-17 US disclosed
WO-2005058892-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188812-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS KLK5, KLK2, KLKB1 ALDH1A1 3986/4885TDP1 2508/4885TAAR1 4635/4885
US-20080132536-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4C ALDH1A1 842/4885TDP1 1418/4885TAAR1 1318/4885
US-11691962-B2 Therapeutic compounds and compositions KLK5, KLK2, KLKB1 ALDH1A1 3986/4885TDP1 2508/4885TAAR1 4635/4885
US-20070111995-A1 Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors PDE4B, PDE3B, PDE4A ALDH1A1 1120/4885TDP1 484/4885TAAR1 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.